Health Care Equipment

QuidelOrtho

QuidelOrtho Reports Q1 2026 Failing to Meet Expectations

QuidelOrtho released FY2026 Q1 earnings on May 5 After-Market (EST), actual revenue USD 619.8 M (forecast USD 659.18 M), actual EPS USD -1.35 (forecast USD -0.71)

QuidelOrtho to release FY2026 Q1 earnings on May 5 After-Market EST, forecast revenue USD 659.18 M, EPS USD -0.71

QuidelOrtho Releases Podcast Episode on High-Sensitivity Troponin's Impact on Cardiac Diagnostics

QuidelOrtho Signs Long-term Strategic Supply Agreement with Lifotronic

QuidelOrtho released FY2025 earnings on February 11 After-Market EST, actual revenue USD 2.73 B (forecast USD 2.707 B), actual EPS USD -16.6932 (forecast USD -15.1887)

QuidelOrtho released FY2025 Q4 earnings on February 11 After-Market (EST), actual revenue USD 0 (forecast USD 700.09 M), actual EPS USD 0 (forecast USD -0.4439)

QuidelOrtho to release FY2025 Q4 earnings on February 11 After-Market EST, forecast revenue USD 699.79 M, EPS USD -0.4439

QuidelOrtho Corporation to Attend Two Healthcare Conferences

QuidelOrtho released FY2025 Q3 earnings on November 5 After-Market (EST), actual revenue USD 699.9 M (forecast USD 663.51 M), actual EPS USD -10.78 (forecast USD -0.455)

QuidelOrtho released FY2025 9 Months Earnings on November 5 After-Market EST, actual revenue USD 2.007 B, actual EPS USD -14.7425

Bonello recommends a moderate buy for QuidelOrtho

QuidelOrtho to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 663.51 M, EPS USD -0.455

QuidelOrtho Corporation Launches FDA Approved New Products

QuidelOrtho released FY2025 Semi-Annual earnings on August 5 After-Market (EST), actual revenue USD 1.307 B, actual EPS USD -3.97

QuidelOrtho released FY2025 Q2 earnings on August 5 After-Market (EST), actual revenue USD 613.9 M (forecast USD 611.88 M), actual EPS USD -3.7725 (forecast USD -1.0257)

QuidelOrtho Earns Multiple Honors in ServiceTrak Awards

QuidelOrtho to Release FY2025 Q2 Earnings on August 5 After-Market (EST), Forecast Revenue USD 611.88 M, EPS USD -1.0257

QuidelOrtho Corporation Announces Future Plans

QuidelOrtho Corporation to Release Q2 2025 Financial Results

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

BiomX

Micware

MetaVia

MicroAlgo

Quantum Cyber NV

QDEL

QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences | QDEL Stock News

StockTitan

QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences | QDEL Stock News

MRNA

IBBQ

LABU

The recent Hantavirus outbreak aboard a cruise ship has shifted market focus to biotech and healthcare stocks. Three companies poised to benefit are Moderna Inc (MRNA), which has a Hantavirus vaccine program, QuidelOrtho (QDEL), which could see increased demand for respiratory diagnostics, and 3M Inc (MMM), a major supplier of protective equipment. Analysts predict significant stock price increases for all three as global health responses intensify.

Invezz

Moderna

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Hantavirus outbreak: these 3 stocks are poised to rip higher

Earnings Watch

QuidelOrtho | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 619.8 M

QuidelOrtho Corporation forecasts 2026 revenue between $2.7B and $2.75B, targeting free cash flow of $100M to $120M amid uncertainties in China pricing. Q1 2026 results showed total revenue of $620M, with a significant decline in respiratory revenue. The company completed the acquisition of LEX Diagnostics, enhancing its point-of-care capabilities. Adjusted EBITDA is expected to be $615M to $630M, with adjusted diluted EPS projected at $1.80 to $2.00. Despite challenges, QuidelOrtho remains focused on improving cash flow and maintaining market share in a competitive landscape.

QuidelOrtho forecasts $2.7B-$2.75B 2026 revenue while targeting $100M-$120M free cash flow amid China pricing uncertainty

QuidelOrtho | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 619.8 M

The acquisition of LEX Diagnostics is anticipated to boost expansion in point-of-care molecular diagnostics, with significant product launches planned in both the U.S. and global markets projected to fuel future growth. The company has shared updates on its financial guidance for the full year of 2026. The announcement was made in San Diego on May 5, 2026, signaling a strategic move towards advancing the company's position in the diagnostic industry.

Unusual Whales

QuidelOrtho Reports First Quarter 2026 Financial Results

GEHC

ISRG

ISUL

QuidelOrtho (QDEL) is set to report earnings tomorrow after market hours. Last quarter, the company exceeded revenue expectations with $723.6 million, a 2.2% year-on-year increase, but missed full-year EPS guidance. Analysts expect a 3.5% revenue decline this quarter. Despite a 21.7% drop in share price recently, analysts maintain a positive outlook, with an average price target of $27 compared to the current price of $12.43. The healthcare equipment sector has seen positive sentiment, with peers like GE HealthCare and Intuitive Surgical reporting strong results.

QuidelOrtho(QDEL.US)

QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences | QDEL Stock News

Hantavirus outbreak: these 3 stocks are poised to rip higher

QuidelOrtho | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 619.8 M

QuidelOrtho forecasts $2.7B-$2.75B 2026 revenue while targeting $100M-$120M free cash flow amid China pricing uncertainty

QuidelOrtho | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 619.8 M

QuidelOrtho Reports First Quarter 2026 Financial Results

QuidelOrtho (QDEL) To Report Earnings Tomorrow: Here Is What To Expect